Drug reference
Elotuzumab is a monoclonal antibody that targets the signalling lymphocytic activation molecule family member 7 (SLAMF7) protein, thereby activating natural killer cells and mediating myeloma cell death.
PDF page 940
Multiple myeloma in patients who have received at least one prior therapy (in combination with lenalidomide and dexamethasone) (specialist use only) ▶BY INTRAVENOUS INFUSION ▶Adult: 10 mg/kg every week, on days 1, 8, 15 and 22 of Immune system and malignant disease cycles 1 and 2, then 10 mg/kg every 2 weeks, on days 1 and 15 of subsequent cycles
PDF page 940
Pre-medication must be administered to minimise the development of infusion-related reactions— consult product literature. secondary primary malignancies CAUTIONS, FURTHER INFORMATION ▶Secondary primary malignancies Manufacturer advises to monitor for the development of secondary primary malignancy before and during treatment with elotuzumab.
PDF page 940
→Appendix 1: monoclonal antibodies
PDF page 940
▶Common or very common Chest pain. cough. deep vein thrombosis. diarrhoea. fatigue. fever. headache. hypersensitivity. increased risk of infection. infusion related reaction. lymphopenia. mood altered. night sweats. numbness. oropharyngeal pain. weight decreased SIDE-EFFECTS, FURTHER INFORMATION Side-effects reported when used in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone. Infusion-related reactions Manufacturer advises for mild-to-moderate infusion reactions interrupt treatment or reduce infusion rate, and monitor closely (consult product literature); permanently discontinue therapy in severe infusion reactions.
PDF page 940
Manufacturer advises effective contraception in men and women of childbearing potential; male patients should continue effective contraceptive measures for 180 days after stopping treatment if their partner is pregnant or of childbearing potential. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 940
Manufacturer advises avoid unless essential—no information available. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938. l HANDLING AND STORAGE Manufacturer advises store in a refrigerator (2–8°C); consult product literature for storage conditions after preparation of the infusion.
PDF page 940
There can be variation in the licensing of different medicines containing the same drug. Powder for solution for infusion EXCIPIENTS: May contain Polysorbates, sucrose ▶Empliciti (Bristol-Myers Squibb Pharmaceuticals Ltd) A Elotuzumab 300 mg Empliciti 300mg powder for concentrate for solution for infusion vials | 1 vial P £1,085.00 Elotuzumab 400 mg Empliciti 400mg powder for concentrate for solution for infusion vials | 1 vial P £1,446.00
PDF page 940
10 mg/kg every week, on days 1, 8, 15 and 22 of
First-line fragment. Read the complete Indications and Dose section above.
PDF page 940
